Skip to main content
SpringerLink
Log in

Management of Patients with Heparin-Induced Thrombocytopenia: Focus on Recombinant Hirudin

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Chong BH, Murray B, Berndt MC, Dunlop LC, Brighton T, Chesterman CN. Plasma p-selectin is increased in thrombotic consumptive platelet disorders. Blood 1994;83:1535–1541.

    Google Scholar 

  2. Warkentin TE, Hayward CP, Boshkov LV, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994;84:3691–3699.

    Google Scholar 

  3. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987;316:581–589.

    Google Scholar 

  4. Warkentin TE. Limitations of conventional treatment options for heparin-induced thrombocytopenia. Semin Hematol 1998;35:17–25.

    Google Scholar 

  5. Warkentin TE, Kelton JE. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502–507.

    Google Scholar 

  6. Wallis DE, Lewis BE, Walenga JM. Failure of current strategies in the prevention of thrombosis in patients with heparin-induced thrombocytopenia: a clinician's perspective. Semin Thromb Hemost 1999;25(suppl 1):3–7.

    Google Scholar 

  7. Greinacher A. Treatment of heparin-induced thrombocytopenia. Thromb Haemost 1999;82:457–467.

    Google Scholar 

  8. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330–1335.

    Google Scholar 

  9. Ganzer D, Gutezeit A, Mayer G. [Potential risks in drug prevention of thrombosis—low-molecular-weight heparin versus standard heparin]. Z Orthop Ihre Grenzgeb 1999;137:457–461.

    Google Scholar 

  10. Alban S, Greinacher A. Role of sulfated polysaccharides in the pathogenesis of heparin-induced thrombocytopenia. In Warkentin TE, Greinacher A, eds. Heparin-induced Thrombocytopenia, New York: Marcel Dekker, 2000:155–174.

    Google Scholar 

  11. Mayo DJ, Cullinane AM, Merryman PK, Horne MK III. Serologic evidence of heparin sensitization in cancer patients receiving heparin flushes of venous access devices. Support Care Cancer 1999;7:425–427.

    Google Scholar 

  12. Pouplard C, May MA, lochmann S, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 1999;99:2530–2536.

    Google Scholar 

  13. Eichler P, Funk S, Albrecht D, et al. HIT-antibodies are not a risk factor for the development of TECs during outpatient heparinization within 6 months after hip or knee replacement—a prospective blinded trial. Ann Hematol 2000;79(suppl 1): A91.

    Google Scholar 

  14. Lindhoff-Last E, Eichler P, Stein M, et al. A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery. Thromb Res 2000;97:387–393.

    Google Scholar 

  15. Greinacher A, Völpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with the immunologic type of heparin-induced thrombocytopenia: a prospective study. Circulation 1999a;99:73–80.

    Google Scholar 

  16. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999b;100:587–593.

    Google Scholar 

  17. Tardy B, Tardy-Poncet B, Fournel P, Venet C, Jospe R, Dacosta A. Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia. Thromb Haemost 1999;82:1199–1200.

    Google Scholar 

  18. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res 1994;74:1–23.

    Google Scholar 

  19. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385–391.

    Google Scholar 

  20. Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998;97;544–552.

    Google Scholar 

  21. Hogg PJ, Jackson CM, Labanowski JK, Bock PE. Binding of fibrin monomer and heparin to thrombin in a ternary complex alters the environment of the thrombin catalytic site, reduces affinity for hirudin, and inhibits cleavage of fibrinogen. J Biol Chem 1996;271:26088–26095.

    Google Scholar 

  22. Hogg PJ, Bock PE. Modulation of thrombin and heparin activities by fibrin. Thromb Haemost 1997;77:424–433.

    Google Scholar 

  23. Hoechst Marion Roussel. Refludan Lepirudin: scientific monograph. New Jersey, USA: Hoeschst Marion Roussel.

  24. Desirudin (Revasc) Product information. Novartis Pharma GmbH, Nürnberg, Germany, 1998.

  25. Lepirudin (HBW 023): Investigators brochure. Behringwerke AG, Marburg/Lahn, Germany. Edition no. 6. 31 January, 1997.

  26. Markwardt F. Development of hirudin as an anti-thrombotic agent. Semin Thromb Haemost 1989;15: 269–282.

    Google Scholar 

  27. Nowak G, Bucha E, Gööck T, Thieler M, Markwardt F. Pharmacology of r-hirudin in renal impairment. Thromb Res 1992;66:707–715.

    Google Scholar 

  28. Nowak G, Bucha E, Goööck T, Prasa D, Thieler H. Pharmakokinetik von Hirudin bei gestörter Nieren-funktion. Hämostaseologie 1991;11:152–157.

    Google Scholar 

  29. Nowak G, Bucha E, Brauns I, Czerwinski R. Anti-coagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long term application of r-hirudin in a haemodialysis patient. Wien Klin Wochenschr 1997;109:354–358.

    Google Scholar 

  30. Vanholder R, Camez A, Veys N, Van Loo A, Dhondt A, Ringoir S. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. Thromb Haemost 1997;77:650–655.

    Google Scholar 

  31. Vanholder R, Camez A, Veys NM, et al. Recombinant hirudin: a specific thrombin-inhibiting anticoagulant for hemodialysis. Kidney Int 1994;45:1754–1759.

    Google Scholar 

  32. Hursting MJ, Alford KL, Becker JC, et al. Novastan (brand of argatroban): a small-molecule, direct thrombin. Semin Thromb Hemost 1997;23:503–516.

    Google Scholar 

  33. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993;70:554–561.

    Google Scholar 

  34. Magnani HN. Orgaran (Danaparoid sodium) use in the syndrome of heparin-induced-thrombocytopenia. Proceedings of a workshop held in London 1996, 1 Nov. Platelets 1997;8:74–81.

    Google Scholar 

  35. Ortel TL, Chong BH. New treatment options for heparin-induced thrombocytopenia. Semin Hematol 1998;35(4 suppl 5):26–34;discussion 35–36.

    Google Scholar 

  36. Meulemann DG. Orgaran (Org 10172): First pharmacological profile in experimental models. Haemostasis 1992;22:58–65.

    Google Scholar 

  37. Skoutakis VA. Danaparoid in the prevention of thromboembolic complications. Ann Pharmacother 1997; 31:876–887.

    Google Scholar 

  38. Chong BH. Danaparoid for the treatment of heparin-induced thrombocytopenia. In Warkentin TE Greinacher A, eds. Heparin-induced Thrombocytopenia. New York: Marcel Dekker, 2000:291–311.

    Google Scholar 

  39. Agnelli G, Iorio A, De Angelis V, Nenci GG. Dermatan sulphate in heparin-induced thrombocytopenia [letter]. Lancet 1994;344:1295–1296.

    Google Scholar 

  40. Greinacher A, Alban S, Dummel V, Franz G, Mueller-Eckhardt C. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost 1995;74:886–892.

    Google Scholar 

  41. Amiral J, Lormeau JC, Marfaing-Koka A, et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997;8:114–117.

    Google Scholar 

  42. Greinacher A. Recombinant hirudin for the treatment of heparin-induced thrombocytopenia. In Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia. New York: Marcel Dekker, 2000:313–338.

    Google Scholar 

  43. Eriksson BI, Ekman S, Lindbratt S, et al. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am 1997;79:326–333.

    Google Scholar 

  44. Eriksson BI, Wille-Jörgensen P, Kälebo P, et al. A comparison of recombinant hirudin with a low-molecular weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997;337:1329–1335.

    Google Scholar 

  45. Hoet B, Tornai I, Arnout J, Close P, Vermylen J, Verstraete M. Open study of intravenous recombinant hirudin (CGP 39393) on platelet function and coagulation in healthy volunteers. Drug Invest 1994;7:127–133.

    Google Scholar 

  46. Breddin HK. Neue Aspekte zu Hirudin. medwelt 1997;48:64–66.

    Google Scholar 

  47. Zoldhelyi P, Webster MWI, Fuster V, et al. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters. Circulation 1993;88:2015–2022.

    Google Scholar 

  48. Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids. Seminars Thromb Haemost 1996;22:197–202.

    Google Scholar 

  49. Verstraete M, Nurmohamed M, Kienast J, et al. European Hirudin in Thrombosis Group. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. J Am Coll Cardiol 1993;22:1080–1088.

    Google Scholar 

  50. Marbet GA, Verstraete M, Kienast J, et al. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers. J Cardiovasc Pharmacol 1993;22:364–372.

    Google Scholar 

  51. Bridey F, Dreyfus M, Parent F, et al. Recombinant hirudin (HBW 023): biological data of ten patients with severe venous thrombo-embolism. Am J Hematol 1995;49:67–72.

    Google Scholar 

  52. Zeymer U, von Essen R, Tebbe U, et al. Recombinant hirudin and front-loaded alteplase in acute myocardial infarction: final results of a pilot study. HIT-I (hirudin for the improvement of thrombolysis). Eur Heart J 1995;16(suppl D)22–27.

    Google Scholar 

  53. Zeymer U, von Essen R, Tebbe U, et al. ALKK Study Group. Frequency of ‘optimal anticoagulation’ for acute myocardial infarction after thrombolysis with front-loaded recombinant tissue-type plasminogen activator and conjunctive therapy with recombinant hirudin (HBW 023). Am J Cardiol 1995;76:997–1001.

    Google Scholar 

  54. Nurmohamed MT, Berckmans RJ, Morrien-Salomons WM, et al. Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment. Thromb Haemost 1994;72:685–692.

    Google Scholar 

  55. Pötzsch B, Hund S, Madlener K, Unkrig C, Muller-Berghaus G. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay. Thromb Res 1997;86:373–383.

    Google Scholar 

  56. Pötzsch B, Madlener K, Seelig C, Riess C, Greinacher A, Müller-Berghaus G. Monitoring of r-hirudin anti-coagulation during cardiopulmonary bypass—assessment of the whole blood ecarin clotting time. Thromb Haemost 1997;77:920–925.

    Google Scholar 

  57. Kornalik F, Blombäck B. Prothrombin activation induced by ecarin—a prothrombin converting enzyme from Echis carinatus venom. Thromb Res 1975;6:57–63.

    Google Scholar 

  58. Nishida S, Fujita T, Kohno N, et al. cDNA cloning and deduced amino acid sequence of prothrombin activator (ecarin) from Kenyan Echis carinatus venom. Biochemistry 1995;34:1771–1778.

    Google Scholar 

  59. Morita T, Iwanaga S, Suzuki T. The mechanism of activation of bovine prothrombin by an activator isolated from Echis carinatus venom and characterization of the new active intermediates. J Biochem 1976;79:1089–1108.

    Google Scholar 

  60. Novoa E, Seegers WH. Mechanisms of alpha-thrombin and beta-thrombin-E formation: use of ecarin for isolation of meizothrombin 1. Thromb Res 1980;18:657–668.

    Google Scholar 

  61. Pötzsch B, Madlener K. Management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia. In Warkentin TE, Greinacher A, eds. Heparin-induced Thrombocytopenia. New York: Marcel Dekker, 2000:355–369.

    Google Scholar 

  62. Schiele F, Vuillemenot A, Kramarz P, et al. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol 1995;50:20–25.

    Google Scholar 

  63. Schiffmann H, Unterhalt M, Harms K, Figulla HR, Völpel H, Greinacher A. Successful treatment of heparin-induced thrombocytopenia (HIT) type II in childhood with recombinant hirudin. Monatsschr Kinderheilkd 1997;145:606–612.

    Google Scholar 

  64. Madei W, Klieser HP, Hoerauf K. Heparin-induced thrombocytopenia as a cause of persistent bleeding after cardiac pacemaker implantation. Dtsch Med Wochenschr 1999;124:487–490.

    Google Scholar 

  65. Wagner AD, Kleber G, Lindner A, Pötzsch B, Fleig WE. 19 jähriger Patient mit generalisiertem Krampfanfall und rezidivierenden Thrombosen unter Heparintherapie. Internist 1998;39:766–769.

    Google Scholar 

  66. Schmidt OH, Lang W. Heparin-induced thrombocytopenia with thromboembolic arterial occlusion treated with recombinant hirudin. N Engl J Med 1997;337:1389.

    Google Scholar 

  67. Harenberg J, Huhle G, Piazolo L, Wang LU, Heene DL. Anticoagulation in patients with heparin-induced thrombocytopenia type II. Sem Thromb Hemost 1997;189–196.

  68. Olbrich K, Wiersbitzky M, Wacke W, et al. A typical heparin-induced thrombocytopenia complicated by intracardiac thrombus, effectively treated with ultralow-dose rt-PA lysis and recombinant hirudin (lepirudin). Blood Coagul Fibrinolysis 1998;9:273–277.

    Google Scholar 

  69. Janssens U, Breithardt OA, Greinacher A. Successful thrombolysis of right atrial and ventricle thrombi encircling a temporary pacemaker lead in a patient with heparin-induced thrombocytopenia type II. Pacing Clin Electrophysiol 1999;22:678–681.

    Google Scholar 

  70. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of two prospective trials to assess the value of parenteral treatement with lepirudin and its therapeutic aPTT range. Blood 2000;96:846–851.

    Google Scholar 

  71. Chong BH. Low molecular weight heparinoid and heparin-induced thrombocytopenia. Aust NZ J Med 1996;26:331.

    Google Scholar 

  72. Lewis BE, Walenga JM, Wallis DE. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemost 1997;23:197–202.

    Google Scholar 

  73. Warkentin TE, Elavathil LJ, Hayward CP, Johnson MA, Russet JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997;127:804–812.

    Google Scholar 

  74. Danaparoid Produkt Information, Organon, Akzo-Organon, Oss, Netherlands, 1999.

  75. Nowak G, Bucha E, Gö öck T, Thieler M, Markwardt F. Pharmacology of r-hirudin in renal impairment. Thromb Res 1992;66:707–715.

    Google Scholar 

  76. Nowak G, Bucha E, Gö öck T, Prasa D, Thieler H. Pharmakokinetik von Hirudin bei gestörter Nierenfunktion. Hämostaseologie 1991;11:152–157.

    Google Scholar 

  77. Nowak G, Bucha E, Brauns I, Czerwinski R. Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long term application of r-hirudin in a haemodialysis patient. Wien Klin Wochesnschr 1997;109:354–358.

    Google Scholar 

  78. Vanholder R, Camez A, Veys N, Van Loo A, Dhondt A, Ringoir S. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. Thromb Haemost 1997;77:650–655.

    Google Scholar 

  79. Vanholder R, Camez A, Veys NM, et al. Recombinant hirudin: a specific thrombin-inhibiting anticoagulant for hemodialysis. Kidney Int 1994;45:1754–1759.

    Google Scholar 

  80. van Wyk V, Badenhorst PN, Luus HG, Kotzé HF. A comparison between the use of recombinant hirudin and heparin during hemodialysis. Kidney Int 1995;48:1338–1343.

    Google Scholar 

  81. van Wyk V, Badenhorst PN, Kotzé HF. The effect of r-hirudin vs heparin on blood-membrane interactions during haemodialysis. Clin Nephrol 1997;8:381–387.

    Google Scholar 

  82. Hempel S, Lubenow N, Greinacher A. Nierenersatztherapie unter r-hirudin (Re¯udan) bei Heparininduzierter Thrombozytopenie Typ II (Abstract). Infusionsther Transfusionsmed 1998;25:5=7p.

    Google Scholar 

  83. Vanholder R, Dhondt A. Recombinant hirudin: clinical pharmacology and potential applications in nephrology. BioDrugs 1999;11:417–429.

    Google Scholar 

  84. Ireland H, Lane DA, Flynn A, Anastassiades E, Curtis JR. The anticoagulant effect of heparinoid Org 10172 during haemodialysis: an objective assessment. Thromb Haemost 1986;55:271–275.

    Google Scholar 

  85. Rowlings PA, Mansberg R, Rozenberg MC, Evans S, Murray B. The use of a low-molecular weight heparinoid (Org 10172) for extracorporeal procedures in patients with heparin-dependent thrombocytopenia and thrombosis. Aust NZ J Med 1991;21:52–54.

    Google Scholar 

  86. Riess FC, Bleese N, Kormann J, et al. Recombinant hirudin is a heparin alternative in cardiac surgery [letter]. Cardiothoracic Vasc Anesthesia 1997;11: 538–539.

    Google Scholar 

  87. Thannheimer A, Preuner JG, Pötzsch B, Birnbaum DE, Völpel A, Greinacher A. Heparin-associated thrombocytopenia in open-heart surgery: heparin or hirudin as anticoagulant: the antibody decides. Ann Hematol 1996;72(suppl I):P222.

    Google Scholar 

  88. Koster A, Kuppe H, Hetzer R, Sodian R, Crystal GJ, Mertzluff F. Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin. Anesthesiology 1998;89:777–780.

    Google Scholar 

  89. Pötzsch B, Iversen S, Riess FC, et al. Recombinant hirudin as an anticoagulant in open-heart surgery: a case report (Abstract). Ann Hematol 1993;68(suppl 2): A46.

    Google Scholar 

  90. Pötzsch B, Riess FC, Völpel H, Müller-Berghaus G, Greinacher A. Recombinant hirudin as anticoagulant during open-heart surgery (Abstract). Thromb Haemost 1995;73:1456.

    Google Scholar 

  91. Pötzsch B, Greinacher A, Riess FC, Madlener K, Völpel H, Müller-Berghaus G. Recombinant hirudin as anticoagulant in cardiac surgery: experiences with eleven patients (Abstract). Annal Hematol 1996; 72:A4.

    Google Scholar 

  92. Riess FC, Löwer C, Seelig C, et al. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: Successful for aortic valve replacement in man. J Thorac Cardiovasc Surg 1995;110:265–267.

    Google Scholar 

  93. Riess FC, Pötzsch B, Bader R, et al. A case report on the use of recombinant hirudin as an anticoagulant for cardiopulmonary bypass in open heart surgery. Eur J Cardiothoracic Surg 1996;10:386–368.

    Google Scholar 

  94. Riess FC, Pötzsch, Mueller-Berghaus G. Recombinant hirudin as an anticoagulant during cardiac surgery. In Pifarré R, ed. New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley & Belfus, Inc. 1997:197–222.

    Google Scholar 

  95. Magnani HN, Beijering RJR, ten Cate JW, Chong BH. Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. In Pifarré R, ed. New Anticoagulants for the Cardio-vascular Patient. Philadelphia: Hanley & Belfus, 1997.

    Google Scholar 

  96. Ranze O, Ranze P, Magnani HN, Greinacher A. Heparin-induced thrombocytopenia in paediatric patient-review of the literature and a new case treated with danaparoid sodium. Eur J Pediatr 1999;158(Suppl 3):S130-S133.

    Google Scholar 

  97. Markwardt F, Fink G, Kaiser B, et al. Pharmacological survey of recombinant hirudin. Pharmazie 1988;43:202–207.

    Google Scholar 

  98. Lepirudin (HBW 023): Investigators brochure. Behringwerke AG, Marburg/Lahn, Germany. Edition no. 6, 31 January, 1997.

  99. Huhle G, Geberth M, Hoffmann U, Heene DL, Harenberg J. Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin. Gynecol Obstet Invest 2000;49:67–69.

    Google Scholar 

  100. Lindhoff-Last E, Willeke A, Mosch G, Nowak G, Ehrly AM, Bauersachs R. Hirudin is not detectable in human breast milk (Abstract). Ann Hematol 1999;78(suppl 1):A82.

    Google Scholar 

  101. Greinacher A, Eckhardt T, Mussmann J, Mueller-Eckhardt C. Pregnancy complicated by heparin associated thrombocytopenia: management by a prospectively in vitro selected heparinoid (Org 10172). Thromb Res 1993;71:123–126.

    Google Scholar 

  102. Eichler P, Friesen HJ, Lubenon N, Jaeger B, Greinacher A. Autilirardin antibodies in patients with heparin-induced thrombocytopenia treated with lepitudin: incidence, effects on a PTT, and clinical relevance. Blood 2000;96:2373–2378.

    Google Scholar 

  103. Huhle G, Song X, Wang LC, Hoffmann U, Harenberg J. Generation and disappearance of antihirudin anti-bodies during treatment with r-hirudin. Fibrinol Proteol 1998;12(suppl 2):91–113.

    Google Scholar 

  104. Huhle G, Hoffmann U, Song XH, Heene DL, Harenberg J. Immunantwort auf rekombinantes Hirudin: eine übersicht (Immune Response to Recombinant Hirudin: an Overview). Haemostaseologie 1999;19: 50–54.

    Google Scholar 

  105. Huhle, G, Hoffmann U, Song X, Wang LC, Heene DL, Harenberg J. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. Br J Haematol 1999;106:195–201.

    Google Scholar 

  106. Newman PM, Swanson RL, Chong BH. IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost 1998;80:292–297.

    Google Scholar 

  107. Insler SR, Kraenzler EJ, Barholomew JR, Kottke-Merchant K, Lytle B, Starr NJ. Thrombosis during the use of the heparinoid Organon 10172 in a patient with heparin-induced thrombocytopenia. Anesthesiology 1997;86:495–498.

    Google Scholar 

  108. Warkentin TE. Danaparoid (Orgaran) for the treatment of heparin-induced thrombocytopenia (HIT) and thrombosis: effects on in vivo thrombin and cross-linked fibrin generation, and evaluation of the clinical significance of in vitro cross-reactivity of danaparoid for HIT-IgG. Blood 1996;88:626a.

    Google Scholar 

  109. Greinacher A, Warkentin TE. Treatment of heparin-induced thrombocytopenia: an overview. In Warkentin TE, Greinacher A, eds. Heparin-induced Thrombocytopenia. New York: Marcel Dekker, 2000:261–290.

    Google Scholar 

  110. Warkentin TE, Kelton JG. Timing of heparin-induced thrombocytopenia (HIT) in relation to previous heparin use: absence of an anamnestic immune response, and implications for repeat heparin use in patients with a history of HIT. Blood 1998;92(suppl 1):182a.

    Google Scholar 

  111. Kempf R, Eichner A, Lubenow N, Ranze O, Greinacher A. Heparin-induced thrombocytopenia: temporal pattern of platelet counts in patients being firstly exposed or reexposed to heparin. Ann Hematol 2000;79(suppl 1):A92.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ernst-Moritz-Arndt University, Department of Transfusion Medicine, Greifswald, Germany

    Norbert Lubenow & Andreas Greinacher

Authors
  1. Norbert Lubenow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Greinacher
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lubenow, N., Greinacher, A. Management of Patients with Heparin-Induced Thrombocytopenia: Focus on Recombinant Hirudin. J Thromb Thrombolysis 10 (Suppl 1), 47–57 (2000). https://doi.org/10.1023/A:1027333320023

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1027333320023

Search

Navigation